Carlit (4275) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Feb, 2026Executive summary
Nine-month net sales decreased 1.5% year-over-year to ¥26,945 million, but operating profit rose 35.0% to ¥2,588 million and profit attributable to owners of parent increased 54.0% to ¥2,254 million, driven by strong performance in several segments and cost control efforts.
Comprehensive income nearly doubled year-over-year, reaching ¥3,954 million, reflecting improved profitability and valuation gains.
The company is in the "Investment Promotion" stage of its medium-term plan, focusing on growth in priority areas such as ammonium perchlorate and new business development.
Financial highlights
Net sales for the nine months ended December 31, 2025, were ¥26,945 million, down 1.5% year-over-year.
Operating profit increased 35.0% to ¥2,588 million; ordinary profit rose 29.9% to ¥2,860 million.
Profit attributable to owners of parent was ¥2,254 million, up 54.0% year-over-year.
Basic earnings per share for the period were ¥98.33, compared to ¥62.12 in the prior year.
Comprehensive income surged 98.3% to ¥3,954 million.
Outlook and guidance
Full-year forecast for FY ending March 31, 2026: net sales ¥38,000 million (+2.9% YoY), operating profit ¥3,500 million (+14.9%), ordinary profit ¥3,700 million (+11.4%), profit attributable to owners of parent ¥2,850 million (+10.9%), and basic EPS ¥125.25.
No revisions to previously announced forecasts.
The Chemical Products segment is expected to remain solid, but Silicon wafers will continue to face operating rate declines due to inventory adjustments.
Latest events from Carlit
- Profits surged on strong segment results; full-year outlook and shareholder returns improved.4275
Q2 202628 Nov 2025 - Operating profit rose 17.7% in Q1 FY2026, but net income fell 18.1% year-over-year.4275
Q1 20268 Aug 2025 - Q1 profits declined on margin pressure, but full-year outlook and financial stability remain solid.4275
Q1 202527 Jul 2025 - Sales up, profits down; margin pressures persist, but recovery expected in H2.4275
Q2 202527 Jul 2025 - Sales up, profit down; FY2026 targets growth and higher shareholder returns.4275
Q4 202527 Jul 2025 - Sales up, profits down as semiconductor and cost pressures persist; full-year outlook revised.4275
Q3 202527 Jul 2025